The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...
Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant as a treatment for major depressive disorder (MDD), blowing a hole in its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . The study included 166 adults with major depressive disorder randomized to receive aticaprant or placebo. At 6 ...
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped development of its rival drug candidate aticaprant as an adjunctive treatment for ...
March 6 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GlobalData on MSN
J&J drops Phase III MDD programme due to lack of efficacy
Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ...
Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive. Topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results